Download Scientific Programme

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Hospital-acquired infection wikipedia, lookup

Sociality and disease transmission wikipedia, lookup

Infection wikipedia, lookup

Neonatal infection wikipedia, lookup

Schistosomiasis wikipedia, lookup

Marburg virus disease wikipedia, lookup

Germ theory of disease wikipedia, lookup

Globalization and disease wikipedia, lookup

Transmission (medicine) wikipedia, lookup

Triclocarban wikipedia, lookup

Gastroenteritis wikipedia, lookup

Clostridium difficile infection wikipedia, lookup

Infection control wikipedia, lookup

Human cytomegalovirus wikipedia, lookup

Antimicrobial copper-alloy touch surfaces wikipedia, lookup

Antimicrobial surface wikipedia, lookup

Urinary tract infection wikipedia, lookup

Anaerobic infection wikipedia, lookup

Antibiotics wikipedia, lookup

Carbapenem-resistant enterobacteriaceae wikipedia, lookup

Staphylococcus aureus wikipedia, lookup

Transcript
Scientific Programme
Tuesday, 10 May
Meet-the-Expert Sessions
Lecture Hall Polymyxins: old becomes new
Amber 2 Experts: Lisa Saiman (New York, US);
07:45 – 08:45
Francesco Menichetti (Pisa, IT)
E443
E446
Objectives
• To describe the mechanism of action of colistin
• To analyse clinical study designs for colistin
in cystic fibrosis and non-CF patients
• To provide examples for the complexity of
in vitro susceptibility and synergy studies
involving colistin
• The risk for the emergence of resistance
to colistin and the ways to prevent this
(combination therapy?)
• Different view on daily dose related to the
PK/PD profile
Lecture Hall Infection prevention and diagnostics in
Amber 3 critically ill patients in the ICU
07:45 – 08:45 Experts: Massimo Antonelli (Rome, IT);
Marc J. Bonten (Utrecht, NL)
E444
Lecture Hall Vertical and horizontal infection control:
Brown 1 pros and cons
07:45 – 08:45 Experts: Margreet Vos (Rotterdam, NL);
Maria Luisa Moro (Bologna, IT)
Lecture Hall Interferon-gamma release assays in TB
Brown 2 diagnosis
07:45 – 08:45
Expert: Roland Diel (Hannover, DE)
E447
Objectives
• attributable mortality of VAP
• diagnosis of VAP
• prevention of VAP (non-antibiotics)
• topical antibiotics to prevent VAP
(SDD and SOD)
Lecture Hall Tropical mycoses: emerging IFIs in Europe?
Amber 4 Experts: Olivier Lortholary (Paris, FR);
07:45 – 08:45
Jacques Meis (Nijmegen, NL)
E445
Objectives
• To identify the epidemiology of travel related
IFI in Europe
• To provide clinic al cases of imported IFI
in both immunocompetent and immunocompromised hosts
• To recognise emerging risk factors for
endemic mycoses
• To realise that endemic fungi can reactivate
late after travel in endemic areas
Arranged with the ESCMID Fungal Infection
Study Group (EFISG)
Objectives
• To understand the differences among
horizontal and vertical infection control
approaches
• To take into account the setting
(epidemiological characteristics, dynamics
of transmission, prevention possibilities,
resources available) when deciding for a
vertical approach
• To discuss horizontal and vertical approaches
with three examples (MRSA, ESBL,
Acinetobacter)
Objectives
• To describe the current evidence on the
accuracy of IGRAs in detecting latent TB
infection
• To gain a better understanding of the role of
IGRAs when considering preventive therapy
• To underscore the advantages of IGRA testing
in immunocompromised patients
• To discuss the topics on which further
research is required
Expert: Christoph Lange (Borstel, DE)
Objectives
• Interferon-gamma release assays for
detecting active TB
Lecture Hall Laboratory identification of beta-lactamases
Silver in Gram-negative strains with multiple enzymes
07:45 – 08:45 Experts: David Livermore (London, UK);
Gian Maria Rossolini (Siena, IT)
E448
Objectives
• To identify which antibiograms suggest the
presence of multiple beta-lactamases
• To know the phenotypic tests to confirm the
presence of multiple enzymes
• To know which genetic tests to apply and when
• To know what to send to a reference lab
.
82
21st ECCMID / 27th ICC / Milan
Final Programme